PORCINE PARVOVIRUS

Abstract

The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

Claims

1-26. (canceled)

27. An isolated virus which is a member of the sub-family Parvovirinae of the family of the Parvoviridae, said virus being characterized in that: a) the virus is an haemorrhagic bowel syndrome (HBS)-associated virus; and b) the virus has a viral genome comprising a gene encoding a Capsid Protein (CP) and a gene encoding a non-structural protein 1 (NS1), wherein the nucleotide sequence of the CP gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1 or the nucleotide sequence of the NS1 gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3.

28. The isolated virus of claim 27, wherein the nucleotide sequence of the CP gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1 and the nucleotide sequence of the NS1 gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3.

29. An isolated virus which is a member of the sub-family Parvovirinae of the family of the Parvoviridae, said virus being characterized in that: a) the virus is an HBS-associated porcine parvovirus; and b) the viral genomic DNA reacts in a PCR reaction with a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 to give a PCR product of 140+/10 base pairs or reacts in a PCR reaction with a primer set of SEQ ID NO: 7 and SEQ ID NO: 8 to give a PCR product of 853+/10 base pairs.

30. The isolated virus of claim 29, wherein the viral genomic DNA reacts in a PCR reaction with a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 to give a PCR product of 140+/10 base pairs and reacts in a PCR reaction with a primer set of SEQ ID NO: 7 and SEQ ID NO: 8 to give a PCR product of 853+/10 base pairs.

31. The isolated virus of claim 27, wherein the nucleotide sequence of the CP gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1 and the nucleotide sequence of the NS1 gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3 and in that the viral genomic DNA reacts in a PCR reaction with a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 to give a PCR product of 140+/10 base pairs and reacts in a PCR reaction with a primer set of SEQ ID NO: 7 and 8 to give a PCR product of 853+/10 base pairs.

32. A cell culture comprising a virus, wherein said culture comprises the virus of claim 27.

33. A DNA fragment comprising a gene encoding a Capsid Protein (CP) wherein the nucleotide sequence of said gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1.

34. The CP encoded by the DNA fragment of claim 33.

35. A DNA fragment comprising a gene encoding a NS1, wherein the nucleotide sequence of said gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3.

36. The NS1 encoded by the DNA fragment of claim 35.

37. The DNA fragment of claim 33, wherein the CP gene is under the control of a functional heterologous promoter.

38. A vaccine for combating HBS-associated porcine parvovirus in pigs, wherein said vaccine comprises an immunogenically effective amount of the virus of claim 27 and a pharmaceutically acceptable carrier.

39. The vaccine of claim 38, wherein said virus is in a live attenuated form.

40. The vaccine of claim 38, wherein said virus is in an inactivated form.

41. The vaccine for combating HBS-associated porcine parvovirus in pigs, wherein said vaccine comprises an immunogenically effective amount of the CP of claim 34 and a pharmaceutically acceptable carrier.

42. The vaccine for combating HBS-associated porcine parvovirus in pigs, wherein said vaccine comprises a live recombinant non-parvovirus vector comprising the DNA fragment of claim 37 and a pharmaceutically acceptable carrier.

43. A vaccine for combating HBS-associated porcine parvovirus in pigs, wherein said vaccine comprises the DNA fragment of claim 37 and a pharmaceutically acceptable carrier.

44. An antibody or antiserum reactive with the virus of claim 27.

Description

LEGEND TO THE FIGURES

[0239] FIG. 1: phylogenetic tree indicating the relatedness of the NS1 of the novel porcine parvovirus according to the invention, to the NS1 of other parvoviruses. The novel porcine parvovirus according to the invention is referred to as BOWL.

[0240] FIG. 2: phylogenetic tree indicating the relatedness of the Capsid Protein of the novel porcine parvovirus according to the invention, to the Capsid Protein of other parvoviruses. The novel porcine parvovirus according to the invention is referred to as BOWL.

[0241] FIG. 3: example of hemorrhagic bowel syndrome as seen in Sample set 1 and 2

LITERATURE REFERENCES

[0242] 1) http://www.merckmanuals.comlvet/digestive_system/intestinal_diseases_in_pigs/hemorrhagic_bowel_syndrome_i_npigs.html [0243] 2) Hni et al. (1993) Schweiz Arch Tierheilkd. 135:117-124 [0244] 3) http://www.pork.org/filelibrary/Factsheets/PIGFactsheets/NEWfactSheets/04-01-01g.pdf [0245] 4) Streck et al., Journal of General Virology 92: 2628-2636 (2011) [0246] 5) Ren et al., Virus research 178: 392-397 (2013) [0247] 6) Xiao et al., Veterinary Microbiology 161: 325-330 (2013) [0248] 7) Opriessnig et al., Veterinary Microbiology 163: 177-183 (2013) [0249] 8) Chenbin Li et al., Archives of Virology 158: 1987-1991 (2013) [0250] 9) Xiao et al., Veterinary Microbiology 160: 290-296 (2012) [0251] 10) Cadar et al., Archives of Virology 156: 2233-2239 (2011) [0252] 11) Lau et al., Journal of General Virology 89: 1840-1848 (2008) [0253] 12) Cheung et al., Archives of Virology 155: 801-806 (2010) [0254] 13) Huang et al., Virology Journal 7: 333-336 (2010) [0255] 14) Cheung et al., Archives of Virology 156: 2071-2078 (2011) [0256] 15) Xiao et al., PLoS One 8: e65312. (2013) [0257] 16) Xiao et al., Genome Announcements 1:e00021-12. (2013) [0258] 17) Cheng et al., PLoS One 5: e13583. (2010) [0259] 18) Martinez et al., Vaccine 10: 684-690 (1992) [0260] 19) Casal et al., Biotechnology and Applied Biochemistry 29: 141-150 (1999) [0261] 20) Zhou et al, Virology Journal 7: 366 (2010) [0262] 21) Hao Feng, PlosOne; Jan. 17, 2014, DOI: 10.1371/journal.pone.007957 [0263] 22) Saliki et al., Journ. Gen. Virol. 73: 369-74 (1992) [0264] 23) Brown et al., Journ. of Virol. 65: 2702 (1991) [0265] 24) Baculovirus Expression Vectors, A Laboratory Manual. By David R. O'Reilly, Lois K. Miller, and Verne A. Luckow. Publisher: Oxford University Press, USA ISBN-10: 0195091310 (Sep. 23, 1993), ISBN-13: 978-0195091311 (May 1994). [0266] 25) Baculovirus and Insect Cell Expression Protocols. In: Methods in Molecular Biology, Volume 388 (2007). Editors: David W. Murhammer. ISBN: 978-1-58829-537-8 (Print) 978-1-59745-457-5 (Online) [0267] 26) Fujisaki, Y., and Murikami, Y (1982). Immunity to infection with porcine parvovirus in pigs inoculated with attenuated HT-strain. Natl Inst Anim Health (Tokyo) 22: 36-37 [0268] 27) Chen et al., Virology Journal 8:307 (2011) [0269] 28) Mayer et al., Vaccine 22: 317-328 (2004) [0270] 29) Production of recombinant proteins: novel microbial and eukaryotic expression systems by Gerd Gellissen, ISBN: 3-527-31036-3 [0271] 30) Gerdts et al, Journal of General Virology 78: 2139-2146 (1997) [0272] 31) Gorres et al., Clinical Vaccine Immunology 18: 1987-1995 (2011) [0273] 32) Paul & Mengeling, Am. J. Vet. Res.: 41: 2007-2011 (1980) [0274] 33) Paul & Mengeling, Am. J. Vet. Res.: 45: 2481-2485 (1984) [0275] 34) Fujisaki e& Murakami, Nat. Inst. of Animal Health quarterly (Tokyo) 22: 36-37 (1982) [0276] 35) Mayer and Walter, eds Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987) [0277] 36) Kohler and Milstein, Nature, 256: 495-497 (1975) [0278] 37) Qiu et al., J. Virol. 79: 11035-11044 (2005) [0279] 38) Wang et al., J. Virol. Meth. 200: 41-46 (2014) [0280] 39) Guan et al., J. Virol. 83: 9541-9553 (2009)